Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
BMO Capital Maintains Outperform on Novo Nordisk, Maintains $163 Price Target
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Argus Research Maintains Buy on Novo Nordisk, Raises Price Target to $160
European pharmaceutical giant praised by Goldman Sachs: innovation is king, and three shares received a “buy” rating
Canto Fitzgerald: The Novo Nordisk (NVO.US) rating was reaffirmed and adjusted from an increase in holdings to an increase rating, with a target price of $160.00.
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Novo Nordisk (NVO.US) was first covered by the Bank of Montreal in Canada, giving it an superior market rating, with a target price of $163.00.
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings